BR9305907A - Uso de derivados de substituída para tratamento de esclerose múltipla - Google Patents

Uso de derivados de substituída para tratamento de esclerose múltipla

Info

Publication number
BR9305907A
BR9305907A BR9305907A BR9305907A BR9305907A BR 9305907 A BR9305907 A BR 9305907A BR 9305907 A BR9305907 A BR 9305907A BR 9305907 A BR9305907 A BR 9305907A BR 9305907 A BR9305907 A BR 9305907A
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment
substituted derivatives
formula
represented
Prior art date
Application number
BR9305907A
Other languages
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR9305907A publication Critical patent/BR9305907A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9305907A 1992-02-19 1993-02-18 Uso de derivados de substituída para tratamento de esclerose múltipla BR9305907A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
BR9305907A true BR9305907A (pt) 1997-10-21

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9305907A BR9305907A (pt) 1992-02-19 1993-02-18 Uso de derivados de substituída para tratamento de esclerose múltipla

Country Status (15)

Country Link
US (4) US5310732A (pt)
EP (1) EP0626853B1 (pt)
JP (1) JP2688113B2 (pt)
AT (1) ATE192045T1 (pt)
AU (1) AU682818B2 (pt)
BR (1) BR9305907A (pt)
CA (1) CA2130275C (pt)
CH (1) CH684310A5 (pt)
DE (1) DE69328474T2 (pt)
DK (1) DK0626853T3 (pt)
FI (1) FI943805L (pt)
HU (1) HU218656B (pt)
NO (2) NO309025B1 (pt)
RU (1) RU2130308C1 (pt)
WO (1) WO1993016706A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
EP0642347A4 (en) * 1992-05-19 1997-06-18 Scripps Research Inst USE OF 2-HALO-ADENINE DERIVATIVES AS THERAPEUTIC ACTIVE AGENTS AGAINST CHRONIC-MYELOIC LEUKEMIA.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
WO1995032718A1 (en) * 1994-05-26 1995-12-07 The Scripps Research Institute 2-halo-2'-deoxyadenosine treatement for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
JPH10512549A (ja) * 1994-12-22 1998-12-02 オーソ・フアーマシユーチカル・コーポレーシヨン 可溶性の２−クロロ−２’−デオキシアデノシン配合物
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
MX9706086A (es) * 1995-02-10 1997-10-31 Schering Ag Preparaciones farmaceuticas para inhibicion de tnf.
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1200102A1 (en) * 1999-07-22 2002-05-02 Supergen, Inc. Methods for treating autoimmune diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
JP4555536B2 (ja) * 2000-02-18 2010-10-06 サザン・リサーチ・インスティテュート ２−クロロ−９−（２−デオキシ−２−フルオロ−β−Ｄ−アラビノフラノシル）−９Ｈ−プリン−６−アミンの合成方法
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
WO2002036611A2 (en) 2000-11-01 2002-05-10 The Regents Of The University Of California Immunomodulatory peptides derived from heat shock proteins and uses thereof
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
EP1549141A4 (en) * 2002-09-27 2008-06-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN
CA2500091A1 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
HRP20050925A2 (en) * 2003-03-28 2006-08-31 Ivax Corporation Oral formulations of cladribine
ES2584183T3 (es) * 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
US7488739B2 (en) * 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
EP1699459B1 (en) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
BRPI0517132B8 (pt) 2004-12-22 2021-05-25 Laboratoires Serono S A uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
JP2008524310A (ja) * 2004-12-22 2008-07-10 ラボラトワール セローノ ソシエテ アノニム 多発性硬化症の組み合せ治療
US8658622B2 (en) 2005-01-14 2014-02-25 Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
EP2971287B1 (en) 2013-03-15 2019-08-14 GPB Scientific, LLC On-chip microfluidic processing of particles
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
CA2996529A1 (en) * 2015-08-24 2017-03-02 Gpb Scientific, Llc Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CN119097635A (zh) 2017-11-24 2024-12-10 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
US20240226284A1 (en) 2020-09-10 2024-07-11 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2022184867A1 (en) 2021-03-03 2022-09-09 Merck Patent Gmbh Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572070C3 (de) * 1966-03-12 1979-03-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Kopiermaterial
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
NZ226672A (en) * 1987-10-30 1991-07-26 Hoffmann La Roche 6-amino-9-(2,3-dideoxy-2-fluoro-b-d-threopentofuranosyl)-9h-purine derivatives and pharmaceutical compositions
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
FI943805A7 (fi) 1994-10-19
US5506213A (en) 1996-04-09
JPH07507540A (ja) 1995-08-24
WO1993016706A1 (en) 1993-09-02
NO20000762L (no) 1994-09-13
NO309025B1 (no) 2000-12-04
HU218656B (hu) 2000-10-28
CH684310A5 (de) 1994-08-31
DK0626853T3 (da) 2000-08-07
NO942765L (no) 1994-09-13
DE69328474D1 (de) 2000-05-31
ATE192045T1 (de) 2000-05-15
FI943805A0 (fi) 1994-08-18
JP2688113B2 (ja) 1997-12-08
RU94038043A (ru) 1996-11-20
EP0626853A1 (en) 1994-12-07
RU2130308C1 (ru) 1999-05-20
US5541164A (en) 1996-07-30
US5310732A (en) 1994-05-10
DE69328474T2 (de) 2000-09-28
CA2130275A1 (en) 1993-09-02
NO322328B1 (no) 2006-09-18
US5506214A (en) 1996-04-09
HUT68030A (en) 1995-05-29
FI943805L (fi) 1994-10-19
HU9402392D0 (en) 1994-10-28
EP0626853B1 (en) 2000-04-26
CA2130275C (en) 1999-06-29
NO20000762D0 (no) 2000-02-16
NO942765D0 (no) 1994-07-25
AU682818B2 (en) 1997-10-23
AU3724993A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
DK0626853T3 (da) Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
ATE245646T1 (de) Therapeutische nukleoside
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
AU4015697A (en) Bicyclic pyrimidine derivatives and their use as anti-coagulants
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
YU47525B (sh) Zeleno staklo za apsorpciju infracrvenog i ultravioletnog zračenja i automobilsko staklo izradjeno od istog
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
ATE71627T1 (de) Bryostatine.
PH22960A (en) 2-pyrimidinyl-1-piperazine derivatives
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
RU94039284A (ru) Производные пиперазина, способ их получения, фармкомпозиция и ее использование
NO953878D0 (no) Umettede fosfonatderivater av puriner og pyrimidiner
NO932377L (no) Antivirale forbindelser
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
DK0635009T3 (da) Derivater af 2,3-dihydro-2,2,4,6,7-pentaalkyl-5-benzofuraner
SE8107468L (sv) Komposition for behandling av psoriasis pa basis av en 1,8-dihydroxi-9-antron substituerad i 10-stellningen
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
MX9307679A (es) Derivados de furanona utiles en terapia.
ATE179167T1 (de) Antivirale analoge von difluorostaton

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal